Biopharmaceutical company Kintara Therapeutics Inc (Nasdaq: KTRA) announced on Monday that it has commenced a 15-patient clinical trial for REM-001 in cutaneous metastatic breast cancer (CMBC) patients.
The study aims to confirm the planned dose and optimise the trial design, paving the way for a Phase 3 clinical trial initiation.
REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent, will be evaluated for its efficacy, with the primary endpoint being the Best Overall Objective Response Rate (bORR).
Kintara's dedication to developing novel cancer therapies aligns with its REM-001 Therapy program, addressing unmet medical needs in patients.
Dr. Reddy's launches Toripalimab (Zytorvi) in India for nasopharyngeal carcinoma
Lunit and Salud Digna partner to advance AI in medical imaging
Sichuan Kelun-Biotech's sacituzumab tirumotecan receives Chinese regulatory approval
Compugen receives new patent covering COM902 use
Natera Ssecures Medicare coverage for Prospera in single lung transplant patients
TheraCryf receives European patent for Orexin 1 antagonist
Oxford Nanopore and UK Biobank partner to create world's largest epigenetic dataset
Novartis' Kisqali approved in EU for broader population of high-risk early breast cancer patients